Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • galvus

    Tag: galvus

    You Searched For "galvus"
    Morepen Labs adds blockbuster Rivaroxaban, Vildagliptin, UDCA to API portfolio

    Morepen Labs adds blockbuster Rivaroxaban, Vildagliptin, UDCA to API portfolio

    Farhat Nasim14 Oct 2019 8:06 AM GMT
    While two products Rivaroxaban and Vildagliptin will augment Morepen Lab's presence in the cardiac and diabetic segments respectively, the third...
    Fight for Vildagliptin: Natco goes to court against Novartis

    Fight for Vildagliptin: Natco goes to court against Novartis

    Farhat Nasim7 Sep 2019 11:02 AM GMT
    Mumbai: Throwing an indirect challenge at patent holder Novartis, drugmaker Natco Pharma has submitted a fresh application in a Hyderabad court...
    4 Pharma Giants face price fixing allegations on Vidagliptin: CCI starts probe

    4 Pharma Giants face price fixing allegations on Vidagliptin: CCI starts probe

    Ruby Khatun Khatun15 Dec 2017 11:45 AM GMT
    Mumbai: Trouble is mounting for 4 big pharma companies over price fixing of an anti-diabetic drug. An investigation has initiated on drug makers...
    Novartis, Abbott, Emcure face allegations of cartelisation in anti-diabetes drug Vildagliptin

    Novartis, Abbott, Emcure face allegations of cartelisation in anti-diabetes drug Vildagliptin

    savita thakur thakur26 March 2017 6:03 AM GMT
    The Swiss drug maker Novartis and US based Abbott along with domestic companies Emcure and USV Pharma are under the lens of Health Ministry and...

    Popular Stories

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

    © 2020 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X